How to Use This Comparison
Every section that follows evaluates semaglutide compound vs Wegovy against the same five criteria: formulation integrity, supervision requirements, dosing flexibility, cost structure, and availability. These are the factors that separate the two options for a man deciding where to start. Both compounded semaglutide and Wegovy require a valid prescription and physician oversight. Neither is available over the counter, and any source selling injectable semaglutide without a prescription is operating outside the law. The more important question is what kind of medical program surrounds the vial or pen a man ends up with.
Formulation Differences That Matter Clinically
The shorthand version of this comparison is that compounded semaglutide and Wegovy contain the same active ingredient. That’s true at a high level, but it skips a meaningful layer of chemistry. Compounding pharmacies may use semaglutide base, semaglutide sodium, or semaglutide acetate. These are chemically distinct salt forms, and the clinical significance of those differences hasn’t been settled by published head-to-head data. Novo Nordisk’s clinical trials were conducted with its proprietary formulation, not with the salt forms used by compounding pharmacies, so the roughly 15% average body weight loss observed in those trials over 68 weeks to more than two years can’t simply be assumed to transfer.
A related misconception is that compounded semaglutide is a generic version of Wegovy. A generic drug must demonstrate bioequivalence to the brand-name product through an abbreviated approval pathway. Compounded semaglutide hasn’t gone through that process. It’s a pharmacy-prepared medication made from bulk semaglutide ingredients, a legally and clinically different category.
One other distinction worth clearing up: Wegovy’s oral tablet formulation contains SNAC, an absorption enhancer that helps the peptide survive the GI tract. The injectable formulation doesn’t contain SNAC. Since most men comparing semaglutide compound vs Wegovy are looking at weekly injections, the SNAC question is irrelevant to their decision. It would matter if someone were comparing oral tablets to compounded injectables, but that’s a different conversation.
What Quality Control Looks Like for Each Option
Wegovy is manufactured by Novo Nordisk under FDA-regulated production standards. Every batch goes through documented quality checks before it reaches a pharmacy shelf. That level of oversight is built into the product’s FDA approval and isn’t something a patient needs to verify independently.
Compounded semaglutide occupies a different regulatory space. Quality depends on the individual compounding pharmacy’s internal practices, and those practices aren’t publicly standardized in the way that FDA manufacturing requirements are. The distinction between a 503B outsourcing facility and a standard 503A compounding pharmacy matters here. A 503B facility operates under more rigorous FDA oversight, including current good manufacturing practice requirements and regular inspections. A 503A pharmacy compounds medications based on individual prescriptions and is primarily regulated at the state level. Both are legal, but the quality floor is different.
The legal basis for most compounded semaglutide prescriptions right now is the FDA’s drug shortage designation for semaglutide products. While that shortage designation is active, compounding pharmacies are permitted to prepare semaglutide. If the designation ends, the legal landscape shifts, and pharmacies that were compounding under the shortage exemption may no longer be able to do so. This is a regulatory reality that men starting treatment should discuss with their physician. The quality question, in practice, is harder for a patient to evaluate on his own. A physician-led program that vets its compounding pharmacy sources removes that burden from the patient.
Evaluating Both Options Against the Five Criteria
Formulation Integrity
Wegovy wins this criterion. Its manufacturing consistency is documented, its formulation is the one used in the clinical trials, and the efficacy data behind the 2.4 mg maintenance dose belongs to that specific product. In Novo Nordisk’s trials, participants lost an average of approximately 15% of their body weight over 68 weeks to more than two years. Compounded semaglutide concedes this point directly: those trial results can’t be assumed to apply to a different salt form prepared in a different facility. That doesn’t mean compounded semaglutide is ineffective, but the evidence base behind it is thinner.
Supervision Requirements
Both options require a prescription from a licensed physician, so the baseline legal requirement is the same. The real difference is in what happens after the prescription is written. A physician-led medical weight loss program includes baseline labs, structured dose titration review, and ongoing follow-up visits where a clinician evaluates how a man is responding. A prescription-only telehealth model may write the script and check in minimally, if at all. This distinction matters more than which formulation a man chooses. The supervision model is what catches problems early, adjusts dosing when side effects are difficult, and tracks whether the treatment is working.
Dosing Flexibility
Wegovy follows a fixed five-strength titration schedule: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, each supplied in a single-use pen. Compounded semaglutide can be prepared at intermediate doses, which gives a prescribing physician more room to manage tolerability during the ramp-up. For men who struggle with nausea or other GI side effects at a standard step, that flexibility is a genuine advantage. The catch is that it depends entirely on the prescribing physician’s clinical judgment and on the compounding pharmacy’s accuracy in preparing the dose. Flexibility without precision is a risk, not an advantage.
Cost Structure
Wegovy carries a high list price. Insurance coverage requires prior authorization, and approval isn’t guaranteed. Novo Nordisk offers manufacturer savings cards, but those have eligibility limits and don’t apply to every insurance situation. Compounded semaglutide is typically lower cost out of pocket, which is one of the primary reasons men seek it out. Cost is a real and legitimate factor in this decision, and pretending otherwise doesn’t help anyone. Specific pricing varies by pharmacy, program, and insurance situation, so exact figures for either option depend on individual circumstances. What matters is that a man understands what he’s getting for the price: the medication alone, or the medication inside a supervised clinical program that includes labs, monitoring, and physician-guided dose management.
Availability
Wegovy supply has been constrained by documented shortages, particularly at certain dose strengths during the titration schedule. Compounded semaglutide became widely available in large part because of those shortages. As noted above, the FDA shortage designation is the legal basis for most compounded semaglutide prescriptions. If that designation ends and Novo Nordisk restores full supply, the legal status of compounded versions changes. Men starting treatment now should ask their physician a direct question: what happens to my supply if the shortage designation is lifted?
Shared Contraindications and Side Effects Men Should Know Before Starting
Regardless of which option a man chooses, the same contraindications apply. Semaglutide in any form shouldn’t be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It’s also contraindicated in men with diabetic retinopathy or severe kidney problems, including end-stage renal disease.
The interaction with thyroid medications, particularly levothyroxine, is presented inconsistently across sources. Some state that thyroid-affecting medications require approximately two weeks to clear the system before starting semaglutide; others frame it as a harder contraindication. The honest answer is that a prescribing physician needs to review a man’s full medication list before either option is started. This is one of several reasons why a prescription-only model, without labs or medication review, falls short.
Common side effects for both formulations are gastrointestinal: nausea, vomiting, diarrhea, and constipation, particularly during the early titration phase. These tend to improve as the body adjusts, but they’re the main reason some men need slower dose escalation.
One indication that belongs exclusively to Wegovy is the MACE risk reduction in adults with established cardiovascular disease. Wegovy is indicated to reduce the risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in adults with established CVD who are overweight or have obesity. Compounded semaglutide can’t be prescribed for that indication because it isn’t FDA-approved for any indication. For men with known cardiovascular disease, this distinction carries real clinical weight.
What Happens If You Switch or Stop
GLP-1 mediated weight loss isn’t permanent without continued treatment or meaningful lifestyle changes that anchor the metabolic progress. Studies consistently show weight regain after discontinuation, which means the decision to start either option is also a decision about what comes next.
If the FDA shortage designation ends and a man on compounded semaglutide needs to switch to Wegovy, the transition introduces a period of dose uncertainty. The salt forms are different, the delivery devices are different, and the bioavailability may not be identical. A physician who has been tracking that man’s labs, weight trajectory, and side-effect profile over time is far better positioned to manage that switch than a provider who wrote a one-time prescription. This is where the supervision model matters most. A physician-led weight loss program that monitors progress continuously can adjust the plan whether the formulation changes, the dose needs recalibration, or the man decides to taper off treatment entirely.
Verdicts by Situation
Wegovy is the stronger choice for men with established cardiovascular disease who may qualify for the MACE risk-reduction indication, men who want the full clinical trial dataset behind their dose, or men whose insurance will cover it after prior authorization. If the evidence base matters most, Wegovy is the clearer path.
Compounded semaglutide is a reasonable starting point for men who can’t access Wegovy due to cost or supply constraints, provided they’re working with a physician who monitors their response, manages titration, and sources from a reputable compounding pharmacy. Without that supervision layer, the cost savings come with trade-offs that aren’t always visible upfront.
Neither option is appropriate without physician oversight and baseline labs. For men whose weight gain is connected to low testosterone or broader metabolic decline, neither semaglutide option addresses the hormonal picture on its own. A clinic that evaluates both weight and hormone status through testosterone replacement therapy alongside medical weight loss can build a more complete plan. Boston Vitality’s physician-led programs are built around that integrated model, connecting labs, monitoring, and treatment under one clinical team. Schedule your consultation to find out which approach fits your situation.
TLDR
Wegovy and compounded semaglutide share an active ingredient, but the chemistry, oversight, and evidence base behind them differ. Wegovy uses the exact formulation tested in clinical trials, showing about 15 percent body weight loss over 68 weeks to two years, and is manufactured under FDA-regulated quality standards. Compounded semaglutide uses different salt forms prepared by individual pharmacies, with quality depending on whether the facility is a more tightly regulated 503B outsourcing facility or a state-regulated 503A pharmacy. Compounding is currently legal mainly due to an active FDA shortage designation, which could change. Wegovy follows a fixed dosing schedule and carries a cardiovascular risk reduction indication that compounded versions cannot claim. Compounded semaglutide allows more flexible dosing and typically costs less. Both require physician supervision, labs, and monitoring, and neither works well without that oversight.